Herantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s disease

‹ Smartphone-based Assessment of Shoulder Motion in Patients with Facioscapulohumeral Muscular Dystrophy

Smartphone-based measurement of keystroke dynamics in the Phase 2b LUMA in Parkinson’s disease ›